Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Quercetin is a compound found in plants that may prevent multi

Trial Details

NCT ID

NCT06940297

Phase

PHASE2

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Biopsy Procedure
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Ciltacabtagene Autoleucel
Computed Tomography

Locations (sample)

Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

Age ≥ 18 years
Relapsed or refractory multiple myeloma who has had at least 3 prior lines of therapies including a proteasome inhibitor, immunomodulatory drug (IM…
Ciltacabtagene autoleucel (Carvykti) available for patient
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →